The initial development of IFNγ-based tests for TB surveillance requires a powerful stimulation with mitogens or superantigens to effectively demonstrate the functional capacity of the sample or to detect an underlying CMI response suppression, thereby reducing the risk of false-negative test results. The gene discussed is IFNG; the disease is tuberculosis.